MEAI

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotech firm based in Vancouver, has been granted a new patent by the United States Patent and Trademark Office. As the company stated in a press release, this approval marks a significant milestone in Clearmind's efforts to develop...

Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical study of cocaine addiction. “We are thrilled to continuously exhibit positive results of...

Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd. (NASDAQ: SPRC) shared the initial positive pre-clinical results of Clearmind’s novel psychedelic molecule, MEAI, for the treatment of obesity and potential treatment of metabolic...

Psychedelics biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF) has published information pertaining to the safety and efficacy of its flagship molecule, called MEAI or CMND-100, after its pre-IND meeting with the Food and Drug Administration on Wednesday. MEAI is a proprietary psychedelic...